$1.13 Million Q1 2025 Revenue, Up 92% vs. Q1 of 2024 Thanks to Valuable Acquisitions and Organic Growth, Plus AI Drone and Quantum Computing Solutions Advancing in Multiple Industries: ZenaTech, Inc.
$ZENA Makes New Acquisition Offer ZenaTech for US Southeast DaaS Business with a Bolt-On Land Survey
ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical business applications. Since 2017, ZENA has leveraged its software development expertise and grown its drone design and manufacturing capabilities through subsidiary ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes.
With enterprise software customers using branded solutions in law enforcement, health, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, the ZENA portfolio of solutions helps drive exceptional operational efficiencies, accuracy, and cost savings. ZENA operates through seven global offices in North America, Europe, Taiwan and UAE, and is growing a DaaS business model and global partner network.
ZenaDrone, a wholly owned subsidiary of ZENA, develops and manufactures autonomous business drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for industrial surveillance, monitoring, inspection, tracking, process automation and defense applications. Currently, the ZENA ZenaDrone 1000 drone is used for crop management applications in agriculture and critical field cargo applications in the defense sector, the IQ Nano indoor drone is used for inventory management and security in the warehouse and logistics sectors, and the IQ Square is an indoor/outdoor drone designed for land survey and inspections use in commercial and defense sectors.
ZenaTech Advances Its US Southeast DaaS Business with a Bolt-On Land Survey Company Acquisition Offer
On May 20th ZENA announced it has extended an offer to acquire a well-established Florida land survey engineering firm that could serve as a bolt-on to another recently acquired land survey company. The acquisition would strengthen the ZENA Drone as a Service presence in the high-growth Florida market and would be the fourth acquisition in the Southeast region and the fifth acquisition nationally.
The ZENA Drone as a Service or DaaS business model works similarly to Software as a Service (SaaS), but instead of providing software over the internet, this model offers drone technology solutions and services on a subscription or pay-per-use basis. Both business and government customers can conveniently access drones for tasks such as surveying, inspections, security, law enforcement, power washing or precision agriculture solutions without having to buy, operate, or maintain the drones themselves.
The ZENA DaaS model offers customers, including government agencies, builders and developers, construction firms, and farmers, reduced upfront costs as there is no need to purchase expensive drone hardware and software, and convenience as the company manages drone pilots, regulatory certifications, maintenance, and operations. DaaS also offers scalability to companies to use more often or less often based on their needs and enables access to advanced drone technology and applications.
Nearly Double Revenue Year-Over-Year for the First Quarter of 2025
On May 15th ZENA announced financial results for the first quarter 2025 which included the following highlights:
Total revenues for the first quarter of 2025 were $1.13 million, up 92% compared to $591,379 for the first quarter of 2024 primarily due to acquisitions and organic growth.
The ZENA new Drone as a Service or DaaS segment grew from completing two acquisitions of land survey drone servicing companies ─ Oregon-based Weddle Surveying and Florida-based KJM Land Surveying. The Company also signed five LOIs for additional acquisitions.
ZENA acquired Othership, a UK workplace management software company supporting its enterprise SaaS software segment, where it plans to leverage workplace AI and quantum computing productivity solutions targeting business and government customers.
ZENA made investments in longer term growth and in new segment development that caused general and administrative expenses to increase to $5.75 million in Q1 2025 versus about $0.7 million in Q1 of 2024.
ZENA made investments in its subsidiary ZenaDrone's UAE manufacturing capabilities during the quarter, including hiring 35 new engineers and technicians. Also announced was the opening of a drone testing facility in Turkey for beyond-the-line-of-sight drone testing.
ZENA Drone product highlights in Q1 include finalizing the third-generation design and 'production model' of the ZenaDrone 1000 drone that will enable the start of scaling up of production. The company also announced the IQ Square drone has moved from prototype to manufacturing stage.
The commence of work on a heavy-lift gas-powered ZD 1000 model for longer fight times for US defense applications took place during the quarter. Testing also commenced on a new high-density drone battery and a proprietary communications system for this drone.
ZenaDrone is preparing for Green UAS followed by Blue UAS certification required to sell to the US Military. Additionally, it is reviewing and putting in place cybersecurity practices, documentation, and internal controls necessary to apply for this certification.
ZENA further expanded its Taiwan drone component manufacturer ─ Spider Vision Sensors, adding additional engineering and business development staff. It also announced the first Blue UAS-certifiable drone sensors are under development.
ZENA received a letter of support from the U.S. Air Force to use ZenaDrone 1000 for drone cargo delivery, which includes blood transport.
Expanding Drone Exterior Building Power Washing to Dubai, Tapping into Global Drone Cleaning Services Market Growing to USD 13 Billion by 2030
On May 13th ZENA announced expanding its United Arab Emirates (UAE) presence by establishing a new office to sell Drone-as-a-Service (DaaS) offerings based in Dubai. Initially this office will focus on delivering drone-powered cleaning services for building exteriors using the IQ Square drone tethered to a water pipe and electrical cord. ZENA is currently obtaining a permit from the Dubai Civil Aviation Authority to begin power wash testing and operations. Supporting this expansion, ZENA will hire two business development managers and up to four additional drone pilots, with drones supplied from its subsidiary ZenaDrone which has a manufacturing hub in nearby Sharjah.
The global drone power washing market falls under a broader drone cleaning services market category that was valued at approximately USD 4.36 billion in 2023 and is projected to reach USD 13.2 billion by 2030, growing at a compound annual growth rate (CAGR) of almost 17% according to market analyst Valuates Reports, fueled by increasing demand for safe, efficient and cost-effective maintenance solutions.
ZenaDrone Tests Proprietary Camera Enabling IQ Nano Drone Swarms for US Defense Applications and Blue UAS Submission
On May 8th ZENA announced that subsidiary ZenaDrone is testing a new proprietary specialized camera that enables more efficient indoor applications such as inventory and security management, when utilizing IQ Nano drone swarms for commercial and US defense applications.
The new ZENA camera prototype developed by its Taiwan component manufacturing subsidiary, Spider Vision Sensors, in collaboration with its certified electronics manufacturing partner, Suntek Global, will enable faster and more precise collection of data including multiple bar codes simultaneously scanned by multiple drones in a drone swarm. ZENA plans to apply for Blue UAS (Unmanned Aerial Systems) certification that lists and validates drones for military and government use.
Military and Defense departments use small autonomous indoor drones like the 10X10 inch IQ Nano for various applications such as inventory management, indoor building reconnaissance, search and rescue, training simulations, and explosives detection. The ZENA ZenaDrone is also engaged in a paid trial which includes developing drone swarm applications for inventory management and security applications with a multinational auto parts manufacturer customer
Drone as a Service (DaaS) Offerings Expand to Bathymetric Surveys for Underwater Terrain Mapping for Commercial and Government Customers
On May 1st ZENA announced its DaaS offerings have expanded to include bathymetric surveys, a specialized method of mapping underwater terrain using drones equipped with sonar. These surveys are important for critical underwater depth and contour data to support maintenance, dredging, environmental planning, and aquatic development for both commercial and government customers.
The ZENA DaaS bathymetric surveys are now available in South Florida through the recently acquired Wallace Surveying where the team has both golf course and Intracoastal Waterway project relationships and surveying expertise. Utilizing advanced sonar and ZENA drones, high-resolution underwater maps help customers make informed decisions ─ from enhanced water management and lake and channel design strategies, to ensuring long-term sustainability.
According to DataIntelo market research, the global Bathymetry Survey Sonar Market was valued at approximately $1.2 billion in 2023, this market is projected to reach $2.1 billion by 2032, growing at a CAGR of 6.2%. This encompasses sonar systems utilized in bathymetric surveys, including those deployed on drones.
For more information on $ZENA visit: www.zenatech.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Media Contact
Company Name: ZenaTech, Inc.
Contact Person: CEO Shaun Passley, Ph.D.
Email: Send Email
Phone: (647) 249-1622
Address:777 Hornby Street, Suite 600
City: Vancouver
State: British Columbia V6Z 1S4
Country: Canada
Website: http://www.zenatech.com
Source: CAP, LLC
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Honeywell Finalizes Sundyne Acquisition to Boost Its Process Industry Strength
Honeywell International Inc. (NASDAQ:HON) is one of the best Dow stocks to invest in. On June 9, the company announced that it had finalized its $2.16 billion all-cash acquisition of Sundyne from private equity firm Warburg Pincus. Sundyne, known for its advanced pumps and gas compressors used in process industries, is expected to contribute immediately to Honeywell International Inc. (NASDAQ:HON)'s revenue growth, segment margins, and adjusted earnings per share during the first full year of ownership. Sundyne brings strong customer relationships and top-tier technology, which are expected to enhance Honeywell UOP's presence in areas like refining, petrochemicals, LNG, and clean energy. Integrated with the Honeywell Forge platform, the combined offering strengthens Honeywell's position in the energy transition by providing a comprehensive, scalable solution. This acquisition comes on the heels of Honeywell International Inc. (NASDAQ:HON)'s recent announcement to spin off its Aerospace Technologies and Solstice Advanced Materials units, moves aimed at creating three separate publicly traded companies, each with focused strategies and growth opportunities. Since December 2023, Honeywell has pursued several strategic initiatives to boost organic growth and streamline its operations, including $13.5 billion in value-enhancing acquisitions. The company operates globally across a wide range of industries. HON has surged by over 7% in the past 12 months. While we acknowledge the potential of HON as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
How major US stock indexes fared Wednesday, 6/11/2025
Wall Street's rally stalled after stocks climbed back within 2% of their all-time high. The S&P 500 slipped 0.3% Wednesday, marking its first drop in four days. The Dow Jones Industrial Average ended little changed, and the Nasdaq composite lost 0.5%. The action was stronger in the bond market, where Treasury yields eased after a report showed inflation ticked up by less last month than economists expected. That raised expectations for the Federal Reserve to cut interest rates later this year. Markets didn't react much to the conclusion of two days of trade talks between the U.S. and China. On Wednesday: The S&P 500 fell 16.57 points, or 0.3%, to 6,022.24. The Dow Jones Industrial Average fell 1.10 points, or less than 0.1%, to 42,865.77. The Nasdaq composite fell 99.11 points, or 0.5%, to 19,615.88. The Russell 2000 index of smaller companies fell 8.17 points, or 0.4%, to 2,148.23. For the week: The S&P 500 is up 21.88 points, or 0.4%. The Dow is up 102.90 points, or 0.2%. The Nasdaq is up 85.92 points, or 0.4%. The Russell 2000 is up 15.99 points, or 0.7%. For the year: The S&P 500 is up 140.61 points, or 2.4%. The Dow is up 321.55 points, or 0.8%. The Nasdaq is up 305.08 points, or 1.6%. The Russell 2000 is down 81.92 points, or 3.7%. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
39 minutes ago
- Yahoo
Allarity Therapeutics Announces Changes to Board of Directors
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years. Mr. Høiland is already well-acquainted with Allarity's mission and operations, having served as a strategic consultant to the Company since October 2024. Jesper Høiland is a highly respected industry leader with more than 30 years of experience in global pharmaceutical commercialization and executive leadership. He previously served as President and EVP of Novo Nordisk's U.S. operations, where he led major product launches, pricing strategies, and infrastructure expansion. In addition, he held senior executive roles as President and CEO of Radius Health and as Global Commercial Officer at Ascendis Pharma. Mr. Høiland currently serves as Chairman of SciBase Holding AB and is a board member of ALK-Abello A/S and Flen Health SA. 'We are pleased to welcome Jesper Høiland to the Allarity Board during a period of growing clinical momentum,' said Jerry McLaughlin, Chairman of the Board of Directors at Allarity Therapeutics. 'On behalf of the entire Board, I would also like to thank Joseph Vazzano for his contributions to Allarity. His financial expertise and thoughtful guidance helped strengthen our governance and operational focus during a critical time. We are grateful for his service and wish him the very best in his ongoing endeavors.' Thomas Jensen, CEO of Allarity Therapeutics, added: 'Since Jesper started working with us in his consultancy capacity, I have several times benefited from his experience and strategic advice. His deep understanding of how to prepare for the commercialization phase of an investigational drug, his extensive global network—built over decades at Novo Nordisk—and his proven leadership during periods of strategic transition at Radius Health will certainly be valuable to Allarity. It is very positive that he will now be even more closely engaged with the Company, as we prepare for the next phases of clinical development and potential later commercialization of stenoparib.' About StenoparibStenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and the Drug Response Predictor – DRP® Companion DiagnosticAllarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed Allarity TherapeuticsAllarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social MediaLinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the anticipated contributions of Jesper Høiland to Allarity's strategic direction; expectations about the Company's clinical and commercial development of stenoparib; the Company's ability to benefit from enhanced leadership and governance; and the potential future impact of board changes on corporate strategy and stakeholder value. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to risks related to changes in leadership not yielding expected outcomes; uncertainties around clinical development timelines; risks that clinical data may not support regulatory approval or commercial viability; and the general risks associated with operating a clinical-stage biopharmaceutical company. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: investorrelations@ Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 tsp@ Attachment Allarity Therapeutics Press Release - Announces Changes to Board of DirectorsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
